NRF2 activation by cysteine as a survival mechanism for triple-negative breast cancer cells
Laura Bottoni,Alberto Minetti,Giulia Realini,Elena Pio,Daniela Giustarini,Ranieri Rossi,Chiara Rocchio,Lorenzo Franci,Laura Salvini,Orazio Catona,Romina D’Aurizio,Mahdi Rasa,Emanuele Giurisato,Francesco Neri,Maurizio Orlandini,Mario Chiariello,Federico Galvagni
DOI: https://doi.org/10.1038/s41388-024-03025-0
IF: 8.756
2024-04-11
Oncogene
Abstract:Triple-negative breast cancer (TNBC) is a very aggressive and heterogeneous group of tumors. In order to develop effective therapeutic strategies, it is therefore essential to identify the subtype-specific molecular mechanisms underlying disease progression and resistance to chemotherapy. TNBC cells are highly dependent on exogenous cystine, provided by overexpression of the cystine/glutamate antiporter SLC7A11/xCT, to fuel glutathione synthesis and promote an oxidative stress response consistent with their high metabolic demands. Here we show that TNBC cells of the mesenchymal stem-like subtype (MSL) utilize forced cystine uptake to induce activation of the transcription factor NRF2 and promote a glutathione-independent mechanism to defend against oxidative stress. Mechanistically, we demonstrate that NRF2 activation is mediated by direct cysteinylation of the inhibitor KEAP1. Furthermore, we show that cystine-mediated NRF2 activation induces the expression of important genes involved in oxidative stress response, but also in epithelial-to-mesenchymal transition and stem-like phenotype. Remarkably, in survival analysis, four upregulated genes ( OSGIN1 , RGS17 , SRXN1 , AKR1B10 ) are negative prognostic markers for TNBC. Finally, expression of exogenous OSGIN1, similarly to expression of exogenous NRF2, can prevent cystine depletion-dependent death of MSL TNBC cells. The results suggest that the cystine/NRF2/OSGIN1 axis is a potential target for effective treatment of MSL TNBCs.
oncology,genetics & heredity,biochemistry & molecular biology,cell biology